Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
Send Cancel

Pirbright Institute begins testing coronavirus vaccines on animals
The pig immune system is closely related to humans.

Scientists join global battle to help control the pandemic

Scientists at The Pirbright Institute have begun testing new coronavirus vaccines for their ability to protect against SARS-CoV-2, the strain responsible for the COVID-19 coronavirus pandemic.

The work, which is being carried out in collaboration with the University of Oxford and Public Health England (PHE), will test new vaccines for their ability to induce protective antibodies against SARS-C0V-2.

Among them includes a chimpanzee adenovirus vaccine vector (ChAdOx1), which is soon to enter human phase I clinical trials and has been used to create vaccines for diseases like Ebola and Middle Eastern respiratory syndrome (MERS).

Each vaccine candidate used in the trial will contain the spike protein from SARS-CoV-2, the protein against which protective antibodies are generated in infected patients. The vaccines will be administered to pigs, and the team will assess whether the antibodies can block SARS-CoV-2 from infecting cells.

The pig immune system is closely related to humans, so a good response to a vaccine in the pigs will help researchers predict the success of vaccines for use in humans. Scientists will also assess the safety of the new vaccines and monitor any adverse effects in the pigs.

Pirbright director, Professor Bryan Charleston, explained: “The ChAdOx1 vector vaccine developed by Oxford will be used in this SARS-CoV-2 vaccine research as it can generate a strong immune response with just a single dose.

"The vaccine vector is non-replicating which means it cannot cause ongoing infection in an individual, making it safer to use for those with underlying health conditions like diabetes. This approach has been used in other vaccines and we are hopeful that this research will enable this vaccine to move into the next stage of human testing."

Dr Toby Tuthill, head of the virus programme at Pirbright, added: “This work is a fantastic collaboration between world-leading medical and veterinary scientists in immunology, virology and molecular biology.

“It will provide an evaluation of new SARS-CoV-2 vaccines in a relevant model and will also generate a panel of antibody-based tools which will help us understand virus structure and how it stimulates the immune response. These antibodies could also be developed as additional novel therapeutics to treat COVID-19.”

Become a member or log in to add this story to your CPD history

MSD Animal Health announces three new research bursaries

News Story 1
 MSD Animal Health has announced three new research bursaries for veterinary surgeons in the areas of swine, poultry and aquaculture. The bursaries, worth up to £4,000, add to MSD's existing bursaries in ruminant and companion animal research.

Projects are expected to be completed within one to two years, and the proposals will be judged by university academics to ensure that assessment remains independent. Full project design and application guidelines, including the specific disease/subject areas, can be found on MSD Animal Health's website

Click here for more...
News Shorts
VMD and VPS announce joint open information day

The Veterinary Medicines Directorate (VMD) and the Veterinary Products Committee (VPC) have announced a joint open information day covering topics such as veterinary medicines regulations, antimicrobial resistance, scientific advice and novel therapies.

Taking place on Wednesday 18 November, the virtual event will take the form of a series of pre-recorded webinars and a 'Slido' Q&A session. Links to the webinars and full instructions on how to use Slido will be available on on 18 November. To join the mailing list for the event, email